Characteristics | Adjusted OR (95% CI) | p-value | |
---|---|---|---|
Phase of the trial | Phase 3 versus 4 | 1.68 (1.38–2.04) | <0.0001 |
Intervention | Drug versus other | 1.20 (0.97–1.48) | 0.10 |
Control group | Inactive versus active | 2.19 (1.83–2.61) | <0.0001 |
Sponsorship | Industry (totally or partially) versus academic | 1.57 (1.22–2.03) | 0.0005 |
FDAAA | Subject versus not subject | 1.15 (0.94–1.41) | 0.17 |
Countries | Multiple countries versus single country | 1.58 (1.29–1.93) | <0.0001 |
 | Not reported versus single country | 1.50 (1.14–1.98) | 0.004 |
Sample size | For an increase of 100 patients | 1.002 (0.99–1.005) | 0.20 |